ImmunityBio, Inc. (IBRX)
9.18
-0.82
(-8.20%)
USD |
NASDAQ |
Oct 16, 16:00
9.16
-0.02
(-0.22%)
After-Hours: 20:00
ImmunityBio Net Income (TTM) : -992.42M for June 30, 2026
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -992.42M |
| March 31, 2026 | -854.60M |
| December 31, 2025 | -351.47M |
| September 30, 2025 | -348.69M |
| June 30, 2025 | -367.17M |
| March 31, 2025 | -409.18M |
| December 31, 2024 | -413.64M |
| September 30, 2024 | -587.88M |
| June 30, 2024 | -597.77M |
| March 31, 2024 | -601.40M |
| December 31, 2023 | -583.85M |
| September 30, 2023 | -458.76M |
| June 30, 2023 | -474.28M |
| March 31, 2023 | -430.90M |
| December 31, 2022 | -417.32M |
| September 30, 2022 | -400.55M |
| June 30, 2022 | -377.82M |
| March 31, 2022 | -372.36M |
| December 31, 2021 | -349.85M |
| September 30, 2021 | -290.43M |
| June 30, 2021 | -223.77M |
| March 31, 2021 | -154.48M |
| December 31, 2020 | -92.38M |
| Date | Value |
|---|---|
| September 30, 2020 | -75.89M |
| June 30, 2020 | -69.70M |
| March 31, 2020 | -66.29M |
| December 31, 2019 | -65.79M |
| September 30, 2019 | -67.49M |
| June 30, 2019 | -75.54M |
| March 31, 2019 | -86.59M |
| December 31, 2018 | -96.23M |
| September 30, 2018 | -103.37M |
| June 30, 2018 | -103.71M |
| March 31, 2018 | -99.43M |
| December 31, 2017 | -96.42M |
| September 30, 2017 | -96.17M |
| June 30, 2017 | -104.10M |
| March 31, 2017 | -114.65M |
| December 31, 2016 | -120.81M |
| September 30, 2016 | -173.39M |
| June 30, 2016 | -184.14M |
| March 31, 2016 | -234.73M |
| December 31, 2015 | -208.68M |
| September 30, 2015 | -134.60M |
| June 30, 2015 | -93.10M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (TTM) Benchmarks
| Moderna, Inc. | -3.151B |
| Sarepta Therapeutics, Inc. | -266.10M |
| Arrowhead Pharmaceuticals, Inc. | -272.12M |
| Oncolytics Biotech, Inc. | -30.07M |
| Sangamo Therapeutics, Inc. | -123.33M |